Anti-CD73 monoclonal antibody - Bristol Myers Squibb

Drug Profile

Anti-CD73 monoclonal antibody - Bristol Myers Squibb

Alternative Names: Anti-CD73 MAb - Bristol Myers Squibb

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies
  • Mechanism of Action CD antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 18 Oct 2016 Phase-I clinical trials in Cancer in USA (unspecified route) before October 2016
  • 16 Apr 2016 Preclinical trials in Cancer in USA (unspecified route) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top